Circio issues invitation to R&D and corporate update webcast on 24 November 2025

17 Nov 2025 14:00 CET

* CTO Dr. Thomas B Hansen will present a summary of novel circVec in vitro and
in vivo results and ongoing R&D activities and plans
* CEO Dr. Erik D Wiklund will provide a corporate update

Oslo, Norway, 17 November 2025 -- Circio Holding ASA (OSE: CRNA), a
biotechnology company developing novel circular RNA expression technology for
gene and cell therapy, issues an invitation to a live webcast at 10:00am CET
on Monday 24 November 2025.

In the webcast, CTO Dr. Thomas B Hansen will present Circio s latest in
vitro and in vivo results on the circVec circular RNA expression platform.
Recent findings include design and testing of novel circVec constructs and
extended in vivo screening and validation of circVec for AAV gene therapy.

CEO Dr. Erik D Wiklund will provide a general corporate and strategy update.

Presenters:
CEO Dr. Erik Digman Wiklund
CTO Dr. Thomas Birkballe Hansen

Time: 10:00 CET on 24 November 2025

Click here to access Teams webcast
(https://teams.microsoft.com/l/meetup-join/19%3ameeting_MmU0NTBhMTQtZjljMy00ODc4
LTk4NzQtNzIwMzQwYTljN2U1%40thread.v2/0?context=%7b%22Tid%22%3a%2266b0661a-3ec3-4
8a8-a966-5b0cce82b3fe%22%2c%22Oid%22%3a%223f5f84b0-5521-4c04-bd8a-e185546abe04%2
2%7d)
Meeting ID: 366 918 860 415 63
Passcode: Kn2Pq9pM

Questions can be submitted in advance by email to Erik D Wiklund:
erik.wiklund@circio.com or directly in the live webcast

A recording of the webcast will be made available on the Circio webpage
(http://www.circio.com/)

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 40-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.

More information:
Access the news on Oslo Bors NewsWeb site